|
KMID : 1102220240430030326
|
|
Kidney Research and Clinical Practice
2024 Volume.43 No. 3 p.326 ~ p.336
|
|
|
Anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine and associated factors in Japanese hemodialysis patients
|
|
Keiji Hirai
Masako Shimotashiro
Toshiaki Okumura
Susumu Ookawara
Yoshiyuki Morishita
|
|
|
Abstract
|
|
|
Background: We assessed the anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine in Japanese hemodialysis patients and determined factors associated with the anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine.
Methods: Overall, 64 patients were enrolled in this single-center, prospective, longitudinal study. Anti-SARS-CoV-2 spike antibody titers were compared between hemodialysis patients and 18 healthcare workers. Multiple linear regression analysis was used to identify factors associated with the anti-SARS-CoV-2 spike antibody titer after the third vaccination.
Results: There was no significant difference in anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination between hemodialysis patients and healthcare workers (18,500 [interquartile range, 11,000?34,500] vs. 11,500 [interquartile range, 7,918? 19,500], all values in AU/mL; p = 0.17). Uric acid (standard coefficient [β] = ?0.203, p = 0.02), transferrin saturation (β = ?0.269, p = 0.003), and log?anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.440, p < 0.001) correlated with the log?anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination. In contrast, only the log?anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.410, p < 0.001) correlated with the log? anti-SARS-CoV-2 spike antibody titer 12 weeks after the third vaccination.
Conclusion: The anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine was comparable between hemodialysis patients and healthcare workers. Uric acid concentration, transferrin saturation, and anti-SARS-CoV-2 spike antibody titer before the third dose were associated with the anti-SARS-CoV-2 spike antibody titer after the third dose in Japanese hemodialysis patients.
|
|
|
KEYWORD
|
|
|
BNT162 vaccine, COVID-19, Hemodialysis, SARS-CoV-2
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|